MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Actinium Pharmaceuticals Inc

Open

1.53 -1.92

Overview

Share price change

24h

Current

Min

1.51

Max

1.57

Key metrics

By Trading Economics

Income

9.1M

-6.9M

Profit margin

-821.235

Employees

27

EBITDA

9.1M

-7.5M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+184.81% upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-1.2M

51M

Previous open

3.45

Previous close

1.53

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Oct 2025, 16:58 UTC

Earnings

BMW Trims 2025 View, Citing Weaker Performance in China

7 Oct 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 Oct 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 Oct 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 Oct 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 Oct 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 Oct 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 Oct 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 Oct 2025, 20:44 UTC

Hot Stocks

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 Oct 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 Oct 2025, 19:23 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 Oct 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 Oct 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 Oct 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 Oct 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 Oct 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 Oct 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 Oct 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 Oct 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 Oct 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 Oct 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 Oct 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 Oct 2025, 14:52 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

184.81% upside

12 Months Forecast

Average 4.5 USD  184.81%

High 5 USD

Low 4 USD

Based on 2 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
help-icon Live chat